N Acetyl Cysteine Cognition Randomized Trial: What the Evidence Says

Quick Answer

N Acetyl Cysteine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Clinical studies involving a range of neuropsychiatric disorders have demonstrated that NAC is well tolerated and has a good safety profile.Signs of efficacy have been observed for disorders similarly associated with impulse control including gambling disorderand skin picking,although these studies were relatively small. [Morley Kirsten (2025); evidence level 2]
• A secondary analysis of alcohol consumption in individuals with cannabis use disorder randomised to NAC (2400 mg/day) vs placebo found significant increases in alcohol abstinence and reduction in weekly drinking days for NAC vs placebo. [Morley Kirsten (2025); evidence level 2]
• Schizophrenia (SZ) is associated with neurocognitive dysfunction already in the early phase of the disease. [Khadimallah I (2025); evidence level 4]
• Individuals with SZ show increased oxidative damage and reduced antioxidant capacity. [Khadimallah I (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For n acetyl cysteine cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Morley Kirsten (2025). N-acetyl cysteine for the treatment of alcohol use disorder: study protocol for a multi-site, double-blind randomised controlled trial (NAC-AUD study). DOI: 10.1136/bmjopen-2024-091631. PMCID: PMC12421191. PMID: 40921646. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12421191/
• Khadimallah I (2025). 669. N-ACETYL-CYSTEINE (NAC) INTERVENTION AND MITOCHONDRIAL MECHANISMS IN- EARLY PSYCHOSIS PATIENTS. DOI: 10.1093/ijnp/pyaf052.351. PMCID: PMC12359389. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Acces.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12359389/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.